



February 14, 2024

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

Notice on Booking of Non-operating Income and Extraordinary Losses

Perseus Proteomics Inc. (The Company) announces that the non-operating income and extraordinary losses were booked in the first nine months of the fiscal year 2023. The details are as follows:

1. Non-operating income

The Company has booked foreign exchange gains of 7,457 thousand yen as non-operating income.

2. Extraordinary losses

The Company has booked impairment loss of 146,970 thousand yen for its non-current assets in accordance with the Accounting Standard for Impairment of Fixed Assets and head office relocation expenses of 69,326 thousand yen as announced on November 16, 2022, as extraordinary losses, respectively. Head office relocation expenses is expected to be booked in the fourth quarter of this fiscal year.

3. Impact on financial results

The above items have been fully reflected in the “Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2024” announced today.

END